Browsing ICR Divisions by title
Now showing items 1277-1296 of 4785
-
Development of an intervention to support the implementation of evidence-based strategies for optimising antibiotic prescribing in general practice.
(Springer Science and Business Media LLC, 2021-09-15)BACKGROUND: Trials show that antimicrobial stewardship (AMS) strategies, including communication skills training, point-of-care C-reactive protein testing (POC-CRPT) and delayed prescriptions, help optimise antibiotic ... -
Development of an online research platform for use in a large-scale multicentre study.
Background Participation in research can be beneficial for patients and healthcare providers, but may prove demanding at patient, clinician and organizational levels. Patient representatives are supportive of online research ... -
Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer.
(ELIFE SCIENCES PUBLICATIONS LTD, 2017-08-10)Targeting the activation function-1 (AF-1) domain located in the N-terminus of the androgen receptor (AR) is an attractive therapeutic alternative to the current approaches to inhibit AR action in prostate cancer (PCa). ... -
Development of biomarker assays to dissect subtype-specific heterogeneity and anti-EGFR treatment response in colorectal cancer
(Institute of Cancer Research (University Of London), 2020-08-31)Colorectal cancer (CRC) is the third most frequently diagnosed type of cancer and the second leading cause of cancer deaths worldwide. Although extensive biological heterogeneity at multiple "-omics" levels has been ... -
Development of chemical tool compounds targeting the non-catalytic functions of tankyrase
(Institute of Cancer Research (University Of London), 2023-06-16)Tankyrase (TNKS1 and TNKS2) is a promising target in anti-cancer drug discovery due to its role in regulating cellular processes which are dysregulated in cancer. In addition to catalysing the poly(ADP-ribosyl)ation of ... -
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.
(2019-09)KRAS represents an excellent therapeutic target in lung cancer, the most commonly mutated form of which can now be blocked using KRAS-G12C mutant-specific inhibitory trial drugs. Lung adenocarcinoma cells harboring KRAS ... -
Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study.
(BMC, 2023-07-05)BACKGROUND: Early phase dose-finding (EPDF) trials are crucial for the development of a new intervention and influence whether it should be investigated in further trials. Guidance exists for clinical trial protocols and ... -
Development of daily automated treatment adaptation for MRI-guided radiotherapy of head and neck cancer patients
(Institute of Cancer Research (University Of London), 2024-08-29)Adaptive radiotherapy (ART) using an MR-Linac enables treatment plans to be adapted daily to account for any observed anatomical changes. To adapt these plans effectively, the regions of interest (ROIs) must be re-delineated ... -
Development of machine learning support for reading whole body diffusion-weighted MRI (WB-MRI) in myeloma for the detection and quantification of the extent of disease before and after treatment (MALIMAR): protocol for a cross-sectional diagnostic test accuracy study.
(BMJ PUBLISHING GROUP, 2022-10-05)INTRODUCTION: Whole-body MRI (WB-MRI) is recommended by the National Institute of Clinical Excellence as the first-line imaging tool for diagnosis of multiple myeloma. Reporting WB-MRI scans requires expertise to interpret ... -
Development of methods to assess the predictive power of pre-therapy imaging for selective internal radiation therapy
(Institute of Cancer Research (University Of London), 2020-12-31)Pre-therapy Technetium-99m (99mTc)-MAA SPECT may be used to predict the 90Y absorbed dose in selective internal radiation therapy (SIRT), while post-therapy 90Y bremsstrahlung SPECT may be used to measure the delivered ... -
Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach.
(SAGE PUBLICATIONS LTD, 2018-02-26)Over the past decade, precision cancer medicine has driven major advances in the management of advanced solid tumours with the identification and targeting of putative driver aberrations transforming the clinical outcomes ... -
Development of molecularly targeted agents and immunotherapies in small cell lung cancer.
(ELSEVIER SCI LTD, 2016-06-01)Small cell lung cancer (SCLC) is a smoking-induced malignancy with multiple toxin-associated mutations, which accounts for 15% of all lung cancers. It remains a clinical challenge with a rapid doubling time, early dissemination ... -
Development of novel therapeutic strategies in relapsed advanced/metastatic non-small cell lung cancer
(Institute of Cancer Research (University Of London), 2022-02-28)Recent advances in the treatment of advanced NSCLC include introduction of targeted therapies and immune-checkpoint inhibitors, leading to improvements in survival outcomes. However, significant new challenges and questions ... -
Development of Real-Time Motion-Including Dose Reconstruction on a Unity MR-Linac system
(Institute of Cancer Research (University Of London), 2024-03-12)The first part of my thesis is concerned with estimating the motion of organs and other critical anatomical structures during radiotherapy treatments. I use 2D cine images acquired during MR-Linac treatments and compare ... -
Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution.
(BMC, 2014-08-27)BACKGROUND: Genomic analysis of multi-focal renal cell carcinomas from an individual with a germline VHL mutation offers a unique opportunity to study tumor evolution. RESULTS: We perform whole exome sequencing on four ... -
Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease.
(SPRINGER, 2017-04-01)Diffuse intrinsic pontine glioma (DIPG) is a rare and deadly childhood malignancy. After 40 years of mostly single-center, often non-randomized trials with variable patient inclusions, there has been no improvement in ... -
Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency.
(CELL PRESS, 2016-10-11)Induced pluripotent stem cells (iPSCs) are a powerful tool for disease modeling. They are routinely generated from healthy donors and patients from multiple cell types at different developmental stages. However, reprogramming ... -
Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries.
(ELSEVIER, 2024-03-01)In the past two decades, the treatment of metastatic non-small cell lung cancer (NSCLC), has undergone significant changes due to the introduction of targeted therapies and immunotherapy. These advancements have led to the ... -
Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children: An International Perspective.
(LIPPINCOTT WILLIAMS & WILKINS, 2022-05-01)BACKGROUND AND OBJECTIVES: Opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare disorder of the nervous system that classically presents with a combination of characteristic eye movement disorder and myoclonus, in addition ... -
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
(2020-11)Sarcomas are a heterogeneous group of malignancies with mesenchymal lineage differentiation. The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions as tissue-agnostic oncogenic drivers has led to new ...